Treatment of Streptococcal Meningitis Without Severe Beta-Lactam Allergy
Clinical Scenario
This protocol applies to confirmed or suspected bacterial meningitis caused by Streptococcus pneumoniae in patients who do not have a severe antibiotic (beta-lactam) allergy. The absence of a severe beta-lactam allergy is the key eligibility criterion that defines which antibiotic approach is appropriate.
Allergy Consideration
A cephalosporin antibiotic is the recommended choice when the allergic reaction to beta-lactams is not severe. Patients with a non-severe reaction remain eligible for the first-line cephalosporin regimen described in the full protocol.
Treatment Approach
The regimen is built around a cephalosporin antibiotic given parenterally. A specific alternative cephalosporin is available if the primary agent cannot be used. The complete protocol — including which agent, dosing parameters, and duration — is available via the link below.
Treatment Goal
Clinical recovery by completion of the treatment course
References
- The committee agreed that ceftriaxone should be given as first-line treatment for Streptococcus pneumoniae meningitis, unless contraindicated in which case cefotaxime can be considered.
- The committee agreed that a cephalosporin should still be considered if the nature of the allergic reaction they get is not severe, in accordance with the first line treatment recommended above.
- The committee recommended that people with meningitis caused by Streptococcus pneumoniae should be treated for 10 days with ceftriaxone (or cefotaxime if ceftriaxone contraindicated).
- The committee were aware that insufficient dose can increase the risk of treatment failure and antibiotic resistance; therefore, they agreed to use the maximum dose recommended by the BNF or BNFC or follow local antimicrobial guidance.
- The committee highlighted the practical and resource-use advantages associated with ceftriaxone because the long half-life means that it may be given only once a day.
- The committee considered that it would be cost-effective to recommend stopping intravenous ceftriaxone for Streptococcus pneumoniae meningitis after 10 days providing the person had clinically recovered.